Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis

Abstract

Our analysis found that <i>TERT</i> promoter mutations may be a negative predictor of outcome with IO and are mutually exclusive with <i>PBRM1</i> loss-of-function mutations.